ArticleWiener klinische Wochenschrift2019
The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
Article in Wiener klinische Wochenschrift, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Molecular Pathogenesis of Chronic Myelomonocytic Leukemia and Potential Molecular Targets for Treatment Approaches.Frontiers in oncology · 2021Pooled it
- Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.Journal of hematology & oncology · 2026Trial
- Prevalence and potential associations of the 2022 newly introduced monocyte value for diagnosis of chronic myelomonocytic leukemia in a general Austrian population.Wiener medizinische Wochenschrift (1946) · 2026Article
- Features of RUNX1-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).Wiener medizinische Wochenschrift (1946) · 2025Article
- Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).Wiener medizinische Wochenschrift (1946) · 2025Article
- Characteristics of NRAS-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and an international cohort (cBioPortal).Wiener medizinische Wochenschrift (1946) · 2025Article
- Features of SRSF2-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBioPortal).Wiener medizinische Wochenschrift (1946) · 2025Article
- Characteristics of CBL-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and an international cohort (cBIOPORTAL).Wiener medizinische Wochenschrift (1946) · 2025Article
- Features of KRAS-mutated patients with chronic myelomonocytic leukemia with and without blast transformation in a national (ABCMML) and international cohort (BIOPORTAL).Wiener medizinische Wochenschrift (1946) · 2025Article
- Acute myeloid leukemia in the next-generation sequencing era : Real-world data from an Austrian tertiary cancer care center.Wiener klinische Wochenschrift · 2025Article
- Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Article
- Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Article
- Significance of C-reactive protein in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Article
- Significance of abnormal blood coagulation in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Article
- Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Observational
- Significance of reduced renal function in patients with chronic myelomonocytic leukemia.Wiener medizinische Wochenschrift (1946) · 2023Article
- Article
- Multistep pathogenesis of chronic myelomonocytic leukemia in patients.European journal of haematology · 2022Article
- Impact of age on the cumulative risk of transformation in patients with chronic myelomonocytic leukaemia.European journal of haematology · 2021Article
- Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.European journal of haematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 11 institutions in 3 countries.
Funding
Abstract
In the Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) clinicolaboratory real-life data have been captured from 606 CMML patients from 14 different hospitals over the last 30 years. It is the only large biodatabase worldwide in which functional methods such as semisolid in vitro cultures complement modern molecular methods such as next generation sequencing. This provides the possibility to comprehensively study the biology of CMML. The aim of this study was to compare patient characteristics with published CMML cohorts and to validate established prognostic parameters in order to examine if this real-life database can serve as a representative and useful data source for further research. After exclusion of patients in transformation characteristics of 531 patients were compared with published CMML cohorts. Median values for age, leukocytes, hemoglobin, platelets, lactate dehydrogenase (LDH) and circulating blasts were within the ranges of reported CMML series. Established prognostic parameters including leukocytes, hemoglobin, blasts and adverse cytogenetics were able to discriminate patients with different outcome. Myeloproliferative (MP) as compared to myelodysplastic (MD)-CMML patients had higher values for circulating blasts, LDH, RAS-pathway mutations and for spontaneous myelomonocytic colony growth in vitro as well as more often splenomegaly. This study demonstrates that the patient cohort of the ABCMML shares clinicolaboratory characteristics with reported CMML cohorts from other countries and confirms phenotypic and genotypic differences between MP-CMML and MD-CMML. Therefore, results obtained from molecular and biological analyses using material from the national cohort will also be applicable to other CMML series and thus may have a more general significance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.